See feature article for BSX below
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
BSX analyst ratings and chart
Evercore ISI analyst Vijay Kumar raised estimates and his price target on Boston Scientific (NYSE: BSX) to $23.50 (from $21.50) due to market multiple expansion. The firm maintained a Buy rating.
FY16 EPS was raised from $1.06 to $1.11 mainly due to higher organic revenue growth (mainly from higher stents + structural heart) assumptions and lower OpEx (following an impressive 1Q performance); FY17 EPS was aised from $1.22 to $1.30 due to slightly higher revenues (increased confidence in Watchman) and higher operating margin expansion assumptions; FY18 EPS was raised from $1.44 to $1.50 due to sustainability of revenue growth (contribution from US launch of Lotus TAVR) and base effect (building off of higher base.
Apr-27-16 Reiterated The Benchmark Company Buy $20 → $22
Apr-12-16 Reiterated RBC Capital Mkts Outperform $20 → $22
Mar-17-16 Initiated Nomura Buy
Feb-25-16 Initiated Sun Trust Rbsn Humphrey Buy $21
Nov-12-15 Initiated Citigroup Buy
Oct-28-15 Reiterated Needham Buy $21 → $22
Oct-05-15 Upgrade Raymond James Outperform → Strong Buy
Sep-28-15 Upgrade Needham Hold → Buy $21
Aug-27-15 Upgrade Goldman Neutral → Buy
Jul-23-15 Reiterated The Benchmark Company Buy $19 → $20
May-04-15 Reiterated Deutsche Bank Hold $17 → $19
Apr-29-15 Reiterated Leerink Partners Outperform $18 → $21
Apr-20-15 Reiterated RBC Capital Mkts Outperform $17 → $20
Feb-18-15 Reiterated Oppenheimer Outperform $15 → $16
Feb-05-15 Reiterated Stifel Buy $16 → $17
Feb-05-15 Reiterated Deutsche Bank Hold $14.50 → $16
Feb-05-15 Reiterated CRT Capital Buy $16 → $18
Jan-30-15 Upgrade BMO Capital Markets Market Perform → Outperform $15 → $18
Sep-30-14 Initiated Needham Hold
Jul-08-14 Initiated CRT Capital Buy $16
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.